Almega PL (Nannochloropsis oculata extract)
Almega PL is a standardized extract from Nannochloropsis oculata microalgae containing EPA and DHA omega-3 fatty acids. It supports cardiovascular health by improving lipid profiles and increasing omega-3 biomarkers through enhanced cell membrane incorporation.
Origin & History
Almega PL is a branded omega-3 supplement oil derived from the microalga Nannochloropsis oculata, containing >25% EPA without DHA. It is produced through extraction methods yielding a polar-lipid rich form with >15% w/w polar lipids, distinguishing it from traditional fish oil supplements.
Historical & Cultural Context
No evidence of traditional medicinal use was identified in the research. Almega PL represents a modern innovation in algal-derived supplements, developed as an alternative to fish oil for omega-3 supplementation.
Health Benefits
• Increases Omega-3 Index by 15.5% (from 4.97% to 5.74%) after 12 weeks - based on RCT evidence • Reduces VLDL cholesterol by 25% - demonstrated in placebo-controlled trial • Lowers triglycerides by 14.2% in 6-month cohort study (n=292) • Decreases total cholesterol by 5% without raising LDL - multiple RCT evidence • Reduces remnant cholesterol by 25% - shown in randomized controlled trial
How It Works
Almega PL delivers EPA and DHA that integrate into cell membrane phospholipids, particularly affecting red blood cell membranes. These omega-3s modulate inflammatory pathways by inhibiting COX-2 and lipoxygenase enzymes while promoting specialized pro-resolving mediators. The algae-derived fatty acids also influence HMG-CoA reductase activity and VLDL synthesis in hepatic tissue.
Scientific Research
Clinical evidence includes a 12-week RCT (n=80, PMID: 32585854) showing significant improvements in Omega-3 Index and VLDL reduction, and a 6-month post-market cohort study (n=292, PMID: 38379539) demonstrating 14.2% triglyceride reduction. Multiple randomized controlled trials confirm consistent lipid-lowering effects without LDL elevation.
Clinical Summary
A 12-week randomized controlled trial demonstrated Almega PL increased omega-3 index from 4.97% to 5.74%, representing a 15.5% improvement. Placebo-controlled studies show 25% reduction in VLDL cholesterol levels. A 6-month cohort study with 292 participants found 14.2% triglyceride reduction and 5% total cholesterol decrease without elevating LDL. Evidence quality is moderate with consistent cardiovascular benefits across multiple endpoints.
Nutritional Profile
Almega PL is a proprietary polar lipid-rich extract derived from Nannochloropsis oculata microalgae, standardized to deliver omega-3 fatty acids in a phospholipid and glycolipid matrix rather than the triglyceride form found in conventional fish oil. Key bioactive lipid fractions include EPA (eicosapentaenoic acid) as the dominant omega-3, primarily esterified to polar lipids (phospholipids and glycolipids), which confers enhanced bioavailability compared to triglyceride-bound EPA — studies suggest polar lipid-bound EPA absorption is meaningfully superior due to lymphatic and portal co-transport mechanisms. The extract contains approximately 8–12% total lipids by weight, with EPA representing a significant proportion of those fatty acids; exact EPA concentration per serving varies by formulation but typical doses in clinical studies range from 1–1.5g of the extract delivering meaningful EPA equivalents. Glycolipids (monogalactosyldiacylglycerol and digalactosyldiacylglycerol) and phospholipids (phosphatidylcholine, phosphatidylethanolamine) serve as the lipid carriers and contribute independently to the lipid-modifying effects. The microalgal matrix also contains chlorophyll pigments, carotenoids including zeaxanthin and beta-carotene at trace levels, and tocopherols (vitamin E) that provide intrinsic oxidative stability. Protein and carbohydrate content in the extract are minimal due to the lipid-extraction process. No significant dietary fiber, mineral, or water-soluble vitamin content has been documented in the isolated extract. Bioavailability is a key differentiator: polar lipid-bound EPA from Almega PL demonstrates faster incorporation into red blood cell membranes and plasma phospholipids compared to ethyl ester or triglyceride forms, consistent with the clinically observed 15.5% increase in Omega-3 Index at relatively modest doses.
Preparation & Dosage
Clinically studied doses range from 900-1100 mg/day of Almega PL capsules (providing 225-275 mg EPA) for 3-6 months. The standardized extract contains >15% w/w polar lipids and >25% w/w EPA. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Vitamin E, CoQ10, Plant sterols, Astaxanthin, Vitamin D3
Safety & Interactions
Almega PL is generally well-tolerated with mild gastrointestinal effects reported in <5% of users. May enhance anticoagulant effects of warfarin and increase bleeding risk when combined with antiplatelet medications. Contraindicated in individuals with fish or shellfish allergies despite algae source. Safety during pregnancy and lactation has not been established in clinical trials.